RLAY Stock Forecast: Relay Therapeutics, Inc. Price Predictions for 2026-2027
The 12 Wall Street analysts covering Relay Therapeutics, Inc. hold a median 12-month price target of $29 — +79.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 80 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Relay Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Issuance (41): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RLAY stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RLAY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +79.9% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Nov 2026 | Jones Trading | Maintains | Buy | — |
| 6 Nov 2026 | Jones Trading | Maintains | Buy | $20 → $31 |
| 20 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $28 → $29 |
| 14 Aug 2026 | JP Morgan | Maintains | Overweight | $28 → $31 |
| 10 Aug 2026 | Citizens | Maintains | Market Outperform | $21 → $26 |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $27 → $30 |
| 21 July 2026 | Goldman Sachs | Maintains | Buy | $22 → $31 |
| 16 July 2026 | Canaccord Genuity | Initiates | Buy | $29 |
| 8 July 2026 | JP Morgan | Initiates | Overweight | — |
| 26 May 2026 | Guggenheim | Maintains | Buy | — |
| 26 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 May 2026 | Barclays | Maintains | Overweight | — |
| 20 May 2026 | Citizens | Maintains | Market Outperform | — |
| 19 May 2026 | Raymond James | Maintains | Strong Buy | — |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 28 Apr 2026 | Goldman Sachs | Maintains | Buy | — |
| 28 Apr 2026 | Oppenheimer | Maintains | Outperform | — |
| 28 Apr 2026 | Wells Fargo | Maintains | Overweight | — |
| 14 Apr 2026 | Jones Trading | Initiates | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RLAY.
This page is one stock. Monday covers all of them.
RLAY appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RLAY vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Relay Therapeutics, Inc. returned +152.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RLAY analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 344.1×
- Price / book
- 4.3×
- EV / EBITDA
- —
Cheaper than 2% of US stocks
Cheaper than 21% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −41.2%
- Return on assets
- −25.5%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Relay Therapeutics, Inc. has a market value of $3.6B and an enterprise value of $2.7B.
Revenue in the twelve months to 30 June 2026: $10.3M. The latest quarter shrank 48.3% year on year.
Net income over the same four quarters: −$286.0M, a −2763.6% net margin.
Diluted earnings per share, trailing twelve months: −$1.57.
Free cash flow in the twelve months to 30 June 2026: −$212.2M.
Relay Therapeutics, Inc. employs 218 people — $47K of revenue per employee.
Data provided by Twelve Data
RLAY and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RLAY’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Relay Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RLAY
What is the RLAY stock price forecast for 2026-2027?
The 12 Wall Street analysts covering Relay Therapeutics, Inc. have a median 12-month price target of $29, with estimates ranging from $25 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RLAY stock a buy right now?
Of the 12 analysts covering Relay Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Relay Therapeutics, Inc. 80 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RLAY?
As at 21 Nov 2026, Relay Therapeutics, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
Will RLAY stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts implies +79.9% from the last close, and Ticker Nerd's factor model ranks Relay Therapeutics, Inc. 80 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RLAY stock forecast for 2030?
No analyst covering Relay Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLAY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $32 over the next 12 months.
How has RLAY stock performed over the past year?
Relay Therapeutics, Inc. returned +152.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Relay Therapeutics, Inc. do?
Relay Therapeutics Inc. is a clinical-stage precision medicines company focused on discovering and developing small-molecule therapies for oncology and genetic disease. The company uses its proprietary Dynamo platform to combine computational modeling, structural biology, medicinal chemistry, and experimental biology in order to address protein targets that have been difficult to drug with conventional methods.
About Relay Therapeutics, Inc.
Relay Therapeutics Inc. is a clinical-stage precision medicines company focused on discovering and developing small-molecule therapies for oncology and genetic disease. The company uses its proprietary Dynamo platform to combine computational modeling, structural biology, medicinal chemistry, and experimental biology in order to address protein targets that have been difficult to drug with conventional methods. Its current pipeline centers on targeted cancer programs, including candidates for genetically defined tumors, as well as selected genetic disease applications. Relay Therapeutics Inc. operates in the biopharmaceutical sector with a strong emphasis on precision oncology, where it aims to design more selective therapies for molecularly characterized diseases. Based in Cambridge, Massachusetts, the company works at the intersection of drug discovery technology and clinical development, making it a notable participant in the small-molecule precision medicine market.
CEO Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS · 218 employees · United States · https://www.relaytx.com